Search clinical trials for: Dose Expansion Doublet: Combination of NKTR-214 nivolumab

Total 53 results

Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Stanford University; Rockefeller University

Active, not recruiting

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

SARCOMA

United States
1ST Biotherapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Advanced Solid Tumor

United States
Bristol-Myers Squibb
Nektar Therapeutics

Terminated

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020)

Ewing Sarcoma | Ependymoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | High-grade Glioma | Leukemia and Lymphoma | Miscellaneous Brain Tumors | Miscellaneous Solid Tumors | Relapsed, Refractory Malignant Neoplasms

United States, Australia, France, Germany, Italy, Spain
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Nektar Therapeutics

Completed

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Advanced Cancer

Japan
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
Famewave Ltd.
Bristol-Myers Squibb

Active, not recruiting

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Melanoma | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Adenocarcinoma | Papillary Thyroid Cancer

Spain, United States, Israel
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Compugen Ltd

Recruiting

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Multiple Myeloma | Ovarian Cancer | Lung Cancer | Advanced Cancer | Colon Cancer | Plasma Cell Neoplasm | HNSCC | Microsatellite Stable Colorectal Carcinoma | MSS-CRC

United States
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Nektar Therapeutics
ImaginAb, Inc.

Withdrawn

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Metastatic Melanoma

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Safety Issues | Efficacy, Self

Mexico
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
AbbVie
AbbVie

Recruiting

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Not yet recruiting

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Bold Therapeutics, Inc.

Active, not recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Colorectal Cancer | Pancreatic Cancer | Cholangiocarcinoma | Gastric Cancers

Korea, Republic of, United States, Canada
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City; Celldex Therapeutics and other collaborators

Completed

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)

Metastatic Castration-resistant Prostate Cancer

United States
Fate Therapeutics

Terminated

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Solid Tumor, Adult

United States
University of Vermont
World Health Organization

Active, not recruiting

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

Poliomyelitis

United States
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
Dong-A ST Co., Ltd.

Recruiting

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Postmenopausal Osteoporosis

Korea, Republic of
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Asthma (NELSON)

Asthma

Italy
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
National Heart, Lung, and Blood Institute (NHLBI)
Novartis

Recruiting

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Severe Aplastic Anemia

United States
University of Zimbabwe
AIDS Care Research in Africa

Completed

Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa

HIV Infections | Cryptococcal Meningitis

Zimbabwe
The Netherlands Cancer Institute
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; GlaxoSmithKline; Merck Sharp... and other collaborators

Recruiting

The Drug Rediscovery Protocol (DRUP Trial) (DRUP)

Cancer | Neoplasm | Tumors | Neoplasia

Netherlands
First Affiliated Hospital of Zhejiang University
Wenzhou Central Hospital

Unknown

Three Induction Treatments on Cryptococcal Meningitis (TITOC)

HIV/AIDS | Cryptococcal Meningitis

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada
University of Washington
National Cancer Institute (NCI)

Withdrawn

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Acute Myeloid Leukemia

United States, Canada, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic Leukemia

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico

Search clinical trials for: Dose Expansion Doublet: Combination of NKTR-214 nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations